MODAFINIL OWL

Modafinil for Idiopathic Hypersomnia: What the Trials Found and What They Leave Open

Yes: modafinil for idiopathic hypersomnia has been tested in randomized, placebo-controlled trials, and it reduced sleepiness compared with placebo.12 The Hypersomnia Foundation lists it among the medicines that help with sleepiness in the disorder.3 Inoue's 2021 paper reported that modafinil was not FDA-approved for IH in the United States.2 Treatment decisions belong with a doctor, who may refer to a sleep specialist.4

Personal account, not medical advice. Modafinil is a prescription medicine, and a Schedule IV controlled substance in the United States. Nothing here is a recommendation to start, stop or change anything. Talk to a doctor.

One boundary before the evidence. I do not have idiopathic hypersomnia. This page summarizes published research, and the personal note near the end is about long-term use in general rather than an account from an IH patient.

What idiopathic hypersomnia is

Inoue and colleagues set out the classification history: in 2005 the ICSD-2 further classified IH into "IH with long sleep time" and "IH without long sleep time", and in 2014 the ICSD-3 unified IH into a single category, defined as central hypersomnia without an increased propensity for rapid eye movement (REM) sleep and with no distinction of whether it is accompanied by long sleep.2 Both randomized trials on this page enrolled patients under the older ICSD-2 criteria, and both limited enrollment to IH without long sleep time.12

Inoue and colleagues note that detailed prevalence figures for IH have not been obtained, and that typical IH has been reported to be 10 times less frequent than narcolepsy.2 Mayo Clinic's page says that people diagnosed with idiopathic hypersomnia have excess sleepiness every day for at least three months, and lists the tools used in diagnosis: the Epworth Sleepiness Scale (a tool for rating one's own sleepiness), a sleep diary, a polysomnogram (a test in a sleep center overnight), and a multiple sleep latency test (which offers a person multiple daytime nap opportunities).4 Mayo's page records that modafinil is a stimulant that can help a person stay awake during the day, and lists possible side effects as headaches, dry mouth, nausea, diarrhea, loss of appetite and weight loss.4

The first randomized trial

Mayer's study title describes it as "a randomized, double-blind, placebo-controlled study" in patients with IH without long sleep time.1 The abstract says the study was performed "with the aim of proving the efficacy of modafinil treatment in these patients", after uncontrolled studies had reported modafinil as efficacious in the treatment of sleep disorders.1

The patients were drug-free, aged over 18 years and with a disease duration of more than two years, and were included under the ICSD-2 criteria.1 After a washout phase, patients at baseline received placebo or 100 mg of modafinil in the morning and at noon over three weeks, followed by a week without medication.1 Between 2009 and 2011 three sleep centers recruited 33 participants.1 The Epworth Sleepiness Scale and the Clinical Global Impression rating scale were recorded at each visit, and Maintenance of Wakefulness Tests (MWTs) were performed at baseline and on days 8 and 21.1

Compared with placebo, modafinil "decreased sleepiness significantly and improved mean sleep latency in the MWT non-significantly".1 On the Clinical Global Impression, the abstract reports that the rating "improved significantly from baseline to the last visit on treatment". It also reports that "the number of reported naps and duration of daytime sleepiness decreased significantly".1 Total sleep time of nocturnal sleep "was slightly reduced".1 The sleep diaries "showed increases in feeling refreshed in the morning", and the daytime diaries showed "significant improvement of performance and of exhaustion".1 The most frequent adverse events were headaches and gastrointestinal disorders, and skin and psychiatric reactions were not reported; the abstract adds that adverse events are "mild to moderate".1 Its conclusion is that modafinil is "an effective and safe medication in the treatment of IH", in a three-week trial of patients with IH without long sleep time.1

The second randomized trial

Inoue's study was conducted at 20 institutions in Japan, and was multicenter, randomized, double-blind, placebo-controlled and parallel-group.2 It ran between April 2014 and August 2015, and patients met the diagnostic criteria for IH in the second edition of the International Classification of Sleep Disorders.2 Of 123 patients screened, 71 were randomized, 34 to modafinil and 37 to placebo, and the modafinil group received 200 mg once daily in the morning, against placebo, across a three-week treatment period.2

The primary endpoint was change in mean sleep latency on the Maintenance of Wakefulness Test, and the paper reports that patients on modafinil experienced a significantly prolonged mean sleep latency on the MWT at the end of the study compared with placebo, a between-group difference of 5.02 minutes (95% confidence interval 3.26 to 6.77; p < 0.001).2 Secondary measures were the Japanese version of the Epworth Sleepiness Scale, the weekly number of daytime naps and the CGI-C scale.2 Adverse events were recorded in 20 of 34 patients on modafinil (58.8%) and 10 of 37 on placebo (27.0%); frequent adverse events in the modafinil group included headache, dry mouth and nausea, and the paper states that no clinically significant adverse events occurred.2 The paper's conclusion is that modafinil was effective and safe for excessive daytime sleepiness in patients with IH without long sleep time.2

Benefit and risk beside narcolepsy

The cohort study by Lavault and colleagues studied 104 patients with IH, 59 of them with long sleep time, alongside 126 patients with narcolepsy with cataplexy.5 The benefits it studied were the Epworth sleepiness score and the opinions of patients and clinicians on a visual analog scale, and the risks it studied were habituation and adverse effects.5 Modafinil was the first-line treatment in 96 to 99% of those patients, and it "produced a similar ESS change in IH patients and in narcolepsy patients (-2.6±5.1 vs. -3±5.1)", with similar benefit as rated by patients and clinicians.5 The change was smaller in IH patients with long sleep time than in those without.5 Sudden loss of efficacy and habituation were rare in both groups.5 Patients with IH reported "similar but more frequent adverse effects with modafinil than narcolepsy patients": nervousness (14%), palpitations (13%) and headache (11%).5 The authors' conclusion is that the balance of benefit against risk in idiopathic hypersomnia, with or without long sleep time, looked similar to the drug's profile in narcolepsy with cataplexy.5

On the regulatory side, the same paper's background records that the European Medicines Agency re-evaluated modafinil's benefit and risk and found the ratio negative for IH because of insufficient data.5 Mayer's abstract dates the withdrawal of the indication for IH to 2010, listed with obstructive sleep apnea and shift work sleep disorder,1 while Inoue's 2021 paper records that modafinil was initially approved by the agency for IH and that the indication was removed in 2011 "because there was a paucity of data from appropriately controlled clinical trials of modafinil for this use".2 The Hypersomnia Foundation's treatment page puts modafinil among the medicines with reasonable evidence for IH or narcolepsy.3

Driving performance

The American Academy of Sleep Medicine's summary of a study published in the journal SLEEP reports that modafinil improves driving performance in patients with narcolepsy and idiopathic hypersomnia.6 Patients were randomly assigned to receive 400 mg of modafinil or a placebo for five days before the driving test, which was a 230 km round trip between 2 p.m. and 4 p.m. on an open highway, and the result reported is that modafinil reduced the mean number of inappropriate line crossings compared with placebo.6 The summary does not report results separately for people with idiopathic hypersomnia.6

Where the evidence is thin

Both randomized trials studied IH without long sleep time, and both ran for three weeks.12 Mayer's trial recruited 33 participants at three sleep centers between 2009 and 2011,1 and Inoue's trial randomized 71 people in Japan only.2

The objective result is the second limit. Mayer's waking test improved but not significantly: the abstract reports that modafinil "improved mean sleep latency in the MWT non-significantly".1 Inoue's trial reached a significant result on that same measure, a prolonged mean sleep latency against placebo.2

The third limit is how the trial groups map onto the diagnosis. Both trials enrolled only people with IH without long sleep time under the ICSD-2 criteria,12 while Inoue records that the ICSD-3 dropped that division in 2014 and defines IH with no distinction of whether it is accompanied by long sleep.2 Inoue's paper also states that few treatments are available for patients with idiopathic hypersomnia.2

A note from a long-term user who does not have IH

To be explicit about the label: I do not have idiopathic hypersomnia, and nothing in this section is an IH patient's account. It is what general long-term use taught me, and it is short on purpose.

The first lesson is tolerance. The two trials above ran for three weeks.12 Lavault's clinic cohort reported that habituation was rare in patients with IH and narcolepsy.5 A single person's long-term use is not evidence against that.

The second lesson is that sleep is the foundation. Modafinil never stood in for sleep.

Questions to take to a sleep specialist

Mayo Clinic notes that a person may be referred to a sleep specialist, and its page lists questions to ask.4 Combined with what the sources above leave open, questions that follow from this include:

  • What is likely causing these symptoms, and what other causes are being ruled out?4
  • Which tests are needed, out of the Epworth Sleepiness Scale, a sleep diary, a polysomnogram and a multiple sleep latency test?4
  • Both randomized trials enrolled only people with IH without long sleep time, a split the newer classification no longer uses. How do those results apply to this diagnosis?12
  • Is the condition likely to be short-term or long lasting?4
  • What does the evidence cover for the length of treatment being discussed, given that both trials ran for three weeks?12
  • What alternatives are there to the first approach suggested?4
  • What monitoring does treatment need, given the cautions the Hypersomnia Foundation lists (psychosis, depression or mania; cardiovascular disease) and the skin and allergic reactions it lists?3
  • Does anything else prescribed interact with it? The Hypersomnia Foundation notes reduced effectiveness of hormonal medicines, including birth control.3

Written by The Night Owl, a long-term user of modafinil who is not a doctor, pharmacist or healthcare provider. This page describes one person's experience alongside published research. It is not medical advice.

Sources

Source types are labeled, so a randomized trial is not presented as the same kind of evidence as a news summary or a treatment information page.

1: Mayer G., Benes H., Young P. and colleagues (randomized, double-blind, placebo-controlled trial). Modafinil in the treatment of idiopathic hypersomnia without long sleep time: a randomized, double-blind, placebo-controlled study. Journal of Sleep Research. 2015. https://pubmed.ncbi.nlm.nih.gov/25196321/

2: Inoue Y., Tabata T. and Tsukimori N. (multicenter randomized, double-blind, placebo-controlled trial). Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study. Sleep Medicine. 2021. https://www.sciencedirect.com/science/article/abs/pii/S1389945721000356 Archived publisher copy of the same paper, read for this page (its abstract, introduction and section summaries): Internet Archive snapshot of 9 March 2024, http://web.archive.org/web/20240309124439/https://www.sciencedirect.com/science/article/abs/pii/S1389945721000356. Supplementary record of the same paper (title, bibliographic data, keyword list): PubMed, https://pubmed.ncbi.nlm.nih.gov/33631500/.

3: Hypersomnia Foundation (patient organization treatment page). Treating people who have idiopathic hypersomnia or narcolepsy. Accessed 25 September 2026. https://www.hypersomniafoundation.org/professionals/treatment/

4: Mayo Clinic (medical center page). Idiopathic hypersomnia. 2024. https://www.mayoclinic.org/diseases-conditions/hypersomnia/diagnosis-treatment/drc-20362338

5: Lavault S., Dauvilliers Y., Drouot X. and colleagues (cohort study). Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Medicine. 2011. https://pubmed.ncbi.nlm.nih.gov/21576035/

6: American Academy of Sleep Medicine (news summary of a study published in SLEEP). Modafinil improves driving performance in people with hypersomnia. 2014. https://aasm.org/modafinil-improves-driving-performance-in-people-with-hypersomnia/